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Abstract
Cyclin E is aberrantly expressed in many types of cancer including breast cancer. High levels of the full length as well as the
low molecular weight isoforms of cyclin E are associated with poor prognosis of breast cancer patients. Notably, cyclin E
overexpression is also correlated with triple-negative basal-like breast cancers, which lack specific therapeutic targets. In this
study, we used siRNA to target cyclin E overexpression and assessed its ability to suppress breast cancer growth in nude
mice. Our results revealed that cyclin E siRNA could effectively inhibit overexpression of both full length and low molecular
weight isoforms of cyclin E. We found that depletion of cyclin E promoted apoptosis of cyclin E-overexpressing cells and
blocked their proliferation and transformation phenotypes. Significantly, we further demonstrated that administration of
cyclin E siRNA could inhibit breast tumor growth in nude mice. In addition, we found that cyclin E siRNA synergistically
enhanced the cell killing effects of doxorubicin in cell culture and this combination greatly suppressed the tumor growth in
mice. In conclusion, our results indicate that cyclin E, which is overexpressed in 30% of breast cancer, may serve as a novel
and effective therapeutic target. More importantly, our study clearly demonstrates a very promising therapeutic potential of
cyclin E siRNA for treating the cyclin E-overexpressing breast cancers, including the very malignant triple-negative breast
cancers.
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Introduction
Cyclin E (cycE), encoded by cyclin E/CCNE1, is an important
cell cycle regulator, which promotes G1/S transition by activation
of Cdk2 kinase activity [1,2]. CycE expression in normal dividing
cells is upregulated at late G1 phase by transcription activation
through E2F family transactivators [3]. The accumulated cycE at
G1/S boundary simultaneously forms complex with Cdk2 and
subsequently promotes initiation of DNA replication and centro-
some duplication. The abundant cycE eventually becomes
phosphorylated and destroyed by ubiquitin-mediated proteolysis
that allows normal cell cycle progression [4–7]. However, the level
of cycE and activity of cycE-Cdk2 can be aberrantly regulated and
this excessive activity of the cycE-Cdk2 complex, in turn, drives
cells to replicate their DNA prematurely, resulting in genome
instability [8,9] and tumorigenesis [10]. In breast cancer, cycE is
overexpressed in ,30% patients [11], including overexpression of
both the full length (50 kDa) and several low molecular weight
(LMW) isoforms (ranging in size from 33 to 45 kD) of cycE protein
[12,13]. Importantly, total levels of cycE (both full length and
LMW isoforms) in tumor tissues are inversely correlated with
survival in patients with breast cancer [14]. The patients whose
cancers show high levels of cycE at stage I die within five years of
diagnosis, while in contrast, cycE-low expressing patients have a
much longer survival, indicating that overexpressed cycE may be
an important cause for breast cancer mortality, and cycE may
serve as an important therapeutic target for the development of
anticancer drugs.
RNA interference (RNAi) is a mechanism for RNA-guided
regulation of gene expression in which double-stranded ribonu-
cleic acid (dsRNA) results in rapid destruction of mRNA
containing the identical sequence as the dsRNA. The functional
mediator of RNAi is ,21-nt siRNAs (small interfering RNAs)
generated by cleavage of dsRNAs via a complex consisting of
Dicer, TAR RNA-binding protein (TRBP) and protein activator
of protein kinase PKR (PACT) [15–17]. In fact, in the past several
years, chemically synthesized siRNA oligos have been proven to be
superior agents that can effectively knockdown gene expression by
sequence-specific degradation of its complementary mRNA in cell
culture. As compared to conventional antisense oligonucleotide
approach, siRNA-mediated gene knockdown is much more
specific and potent. The selection of the targeting sequences of
siRNA is less restricted so the rates of producing effective duplexes
are higher [18]. In addition, siRNA is double stranded RNA,
which is more resistant to nuclease degradation, and therefore it
can have prolonged stability in in vivo studies [19,20]. These
unique properties make siRNAs a promising new class of drugs for
cancer treatment via targeting the mutation- or overexpression-
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shown that siRNA can effectively suppress oncogene expression in
cancer cells [17,21–23] and a couple of siRNA cancer therapies
are indeed in preclinical or early-stage of clinic trials [17]. In this
study, to investigate if cycE can serve as a novel therapeutic target
and if siRNA-based approach can effectively treat cycE-overex-
pressing breast cancer, we employed cycE siRNA to target cycE
overexpression and assessed its ability to suppress breast cancer
growth in nude mice. Our study here clearly demonstrated a very
promising therapeutic potential of cycE siRNA for treatment of




All animal protocol performed in this study was approved by the
Institutional Animal Care and Use Committee at Baylor College
of Medicine (protocol number: AN-3142) and nude mice aged 8–
12 weeks were used for in vivo studies.
Cell culture
All cell lines used here were obtained from ATCC (Rockville,
MD) and cultured at 37uC in a 5% CO2 incubator. Immortalized
normal human mammary epithelial cell line MCF-10A was
cultured in DMEM/F12 with 5% horse serum (Invitrogen),
10 mg/ml insulin, 20 ng/ml EGF, 0.5 mg/ml hydrocortisone and
1% penicillin/streptomycin (Invitrogen). Breast cancer cell lines
including basal type MDA-MB436 (ER-, PR-negative) and MDA-
MB157 (ER-, PR-negative), and luminal type SK-BR3 (ER-, PR-
negative, HER2-overexpressed), MDA-MB453 (ER-, PR-nega-
tive) and T47D (ER-, PR-positive) [24] were cultured in DMEM
supplemented with 10% fetal bovine serum (Invitrogen), 1% L-
glutamine (Invitrogen) and 1% penicillin/streptomycin (Invitro-
gen), while for MDA-MB436, 10 mg/ml insulin was also added
into the above medium.
Transfection with siRNA oligos
The siRNA oligos for cyclin E (cycE) and luciferase (Luc) were
synthesized by Dharmacon Research Inc. The cycE siRNA oligos
corresponded to nucleotides 592 to 610 of the human CCNE1
(variant 1) coding region (GenBank accession number:
NM_001238). The indicated breast cancer cells (1610
5/well)
were transfected with siRNA oligos (0.3 mg/well) in 6-well plates
using Oligofectamine reagent (Invitrogen) following the manufac-
turer’s protocol.
Western blotting analysis
Forty four hours post-transfection, cells were lysed, as indicated,
into mammalian cell lysis buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA,
1 mM DTT) with 5 mM sodium fluoride, 1 mM sodium
orthovanadate, 1 mM phenylmethyl sulfonylflouride, 2 mg/ml
aprotinin, 2 mg/ml leupeptin. After centrifugation at 4uC
(14,000 rpm, 15 min), lysates (20 mg) were analyzed by immuno-
blotting assay. Anti-cycE polyclonal antibody (C-19) was from
Santa Cruz and anti-actin antibody (Ab-1) was from Oncogene
Research (Boston, MA). The densities were determined by
densitometry for each protein band, and the density of cycE was
standardized against that of actin in each sample. The standard-
ized density of cycE in the mock SK-BR3 was arbitrarily set at
100%, and the relative level of cycE in other samples was obtained
by comparing those standardized densities of cycE to that of cycE
in the mock SK-BR3. The data shown here were presented as
means 6 s.d. from at least three independent experiments.
Apoptosis and cell cycle analysis
Standard fluorescence-activated cell sorter (FACS) analysis was
used to determine apoptosis of the cells or the distribution of the
cells in cell cycle. Briefly, the cells were transfected with or without
siRNA. Adherent cells were then collected by trypsinization and
combined with cells floating in the medium. The cell cycle pattern
was analyzed after being stained with propidium iodide, and the
apoptotic cells were simultaneously assessed by flow cytometric
detection of sub-G1 DNA content.
Colony formation assay in soft agar
The standard colony formation assay was performed as
described previously [25]. Briefly, the indicated breast cancer
cells were transfected without (mock) or with siRNA oligos
targeting cyclin E (cycE) or luciferase (Luc). Two days after
transfection, the cells (1610
3 cells/well) were plated in 24-well
plates in culture medium containing 0.35% agar overlying a 0.7%
agar bottom layer and cultured at 37uC with 5% CO2. Three to
five weeks later, the top layer of the culture was stained with
p-iodonitrotetrazolium (1 mg/ml), and colonies (.100 mm) in
diameter were counted. To monitor the cell viability of each
group, the cells (1610
3 cells/well) were also plated in the common
10-cm culture plates with the normal complete medium, and 2–3
weeks later, the colonies were stained with 1% crystal violet, and
counted. The number of colonies in soft agar was normalized by
the cell viability of each group. Finally, the normalized number of
colonies in soft agar for the groups of Luc or cycE was
standardized against the control cells (mock, set at 100%).
In vivo tumor studies
MDA-MB436 (1,2610
6/injected point), SK-BR3 (1,2610
6/
injected point) or T47D (1,2610
6/injected point) mixed with
Matrigel Matrix (BD Biosciences) were injected into the second
pair of the mammary glands of the nude mice (two injected points
per mouse, and 45 mice for each cell line). Twelve days or four
weeks later, the injected nude mice with tumor burden were
randomly divided into 3 groups (n=15 for each group): mock (no
siRNA), Luc siRNA, or cycE siRNA, and then treated without
(mock) or with indicated siRNA complex by intratumoral
injection. Each complex contained 10 mg of siRNA (for mock,
using PBS instead of siRNA) and 7.5 ml Oligofectamine (Invitro-
gen) in PBS, which was mixed according to manufacturer’s
instruction of Oligofectamine. These mice were treated weekly for
4 weeks, and sacrificed 7 days after the last treatment for tumor
size comparison or sacrificed 2 days after the last treatment for
anti-cycE immunohistochemistry or TUNEL assays. The tumor
size was measured just before each treatment or after sacrifice, and
the tumor volume was obtained by the following equation: V=
(length 6 width 6 height)/2 (V is the tumor volume). For
assessment of the effectiveness of combination of cycE siRNA with
doxorubicin (Dox), MDA-MB436 cells were injected into the
second pair of mammary glands of the nude mice as described
above (totally n=75). Beginning on day 14 post the tumor cell
injection, the mice with tumor burden were randomly divided into
5 groups (n=15 for each group): mock (liposome alone), Luc
siRNA, cycE siRNA, Dox (alone), and Dox + cycE siRNA. For the
groups of mock, Luc siRNA or cycE siRNA, the mice were treated
with liposome alone, Luc siRNA (10 mg), or cycE siRNA (10 mg),
respectively, by weekly repeated intratumoral injection for 4
weeks. For the Dox alone group, the mice were only treated with
Dox (2 mg/kg body weight) by weekly intraperitoneal injection
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administered with Dox (2 mg/kg body weight) by weekly
intraperitoneal injection following cycE siRNA treatment on the
next day for 4 weeks. All of the above experiments were repeated
two or three times.
Immunohistochemistry
Tumors were dissected 2 days after the last treatment with mock
or indicated siRNA, and then sectioned, deparaffinized, rehydrat-
ed, and stained with anti-cycE antibody according to manufac-
turer’s instructions of Elite Universal ABC kit (Vector Laborato-
ries). For each treatment group, at least two tumor samples, two
slides per sample were analyzed. For each slide examined, 1000
cells were counted from 6 fields with 200X magnification and the
percentage of cycE-positive cells, compared to total cells, were
indicated on the y axis.
TUNEL assay
Apoptotic cells were confirmed using the In Situ Cell Death
Detection kit from Roche, following the manufacture’s instruction.
The apoptotic cells (purple staining) were counted under a
microscope. The apoptotic index was defined by the percentage
of purple cells among the total cells of each sample. For each cell
line analyzed, 200 cells were counted from the fields with 200X
magnification. As to each tumor sample analyzed, 1000 cells were
counted from the fields with 200X magnification. The experi-
ments were repeated at least three times.
Synergistic analysis of cycE siRNA and Dox in cultured
cells
SK-BR3 and MDA-MB436 cells (1610
4 cells/well) were
transfected with different concentration of cycE siRNA. Twenty-
Figure 1. CycE siRNA is able to remarkably suppress cycE overexpression in breast cancer cell lines. A) Inhibition of cycE overexpression
by cycE siRNA. Indicated cells were transfected with siRNA oligos targeting on either cycE or luciferase (Luc, control). Cells were harvested two days
after transfection. The protein lysates were subjected to Western blotting analysis by using anti-cycE and anti-Actin antibodies, respectively (top
panel). CycE protein levels (full length) from cycE or luc siRNA-treated cells were normalized by Actin. The normalized density of cycE in the mock SK-
BR3 was arbitrarily set at 100%, and the relative level of cycE in other samples was obtained by comparing those normalized densities of cycE to that
of cycE in the mock SK-BR3 (bottom panel). B) Suppression of the expression of LMW isoforms by cycE siRNA. The indicated cells were transfected
with or without siRNA, and the whole lysates were collected and subjected to anti-CycE Western blot analysis. In SK-BR3 and MDA-MB157 cells,
although LMW isoform pattern of cycE was different, the LMW isoforms as well as the full length cycE were inhibited by cycE siRNA. The LMW
isoforms of cycE were undetectable in T47D.
doi:10.1371/journal.pone.0012860.g001
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culture plates and treated with different dosages of Dox for 8 days.
The viable cells were then determined with MTT assay. For MTT
assay, 25 ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide, Sigma) stock solution (5 mg/ml) was added to
each well on the plate. Cells was incubated for 4 hours with MTT
and then lysed in 100 ml of dimethylsulfoxide (DMSO). Conver-
sion of MTT to formazan by metabolically viable cells was
determined by microplate reader at 540 nm wavelength. The
synergistic inhibitory effects were determined with combination
index at IC80, IC90 and IC95 using the CI-isobologram method
developed by Chou-Talalay [26,27].
Statistical analysis
Statistical analysis was carried out using a two-tailed Student’s t-
Test. Data were considered statistically significant at p value #0.05.
Results
CycE overexpression is suppressed in breast cancer cells
by siRNA targeting
To address if cycE can serve as a novel therapeutic target for
breast cancer, we first used siRNA oligos to deplete cycE
expression in breast cancer cells. The selected cycE siRNA
targeted the mRNA sequence near the region encoding the cyclin
box of cycE [23]. The siRNA oligos were transfected into three
cycE-overexpressing breast cancer cell lines (SK-BR3, MDA-
MB157 and MDA-MB436) and two cycE-low expressors (T47D
and MDA-MB453). Protein levels of the full length cycE (50 kD)
were reduced by cycE siRNA up to 96% in all five cell lines
(Figure 1A, lanes 2, 5, 8, 11 and 14 of upper panel; Figure 1A,
lower panel). LMW isoforms of cycE (,45 kDa and ,35 kDa)
were significantly reduced as well (Figure 1B). The inhibitory effect
Figure 2. Apoptosis and decreased cell proliferation induced by depletion of cycE in cycE-overexpressing breast cancer cells. A)
Downregulation of cycE promotes apoptosis of SK-BR3, MDA-MB436 and MDA-MB157, but not T47D and MDA-MB453. Ninety-six hours after siRNA
transfection, the indicated adherent cells were collected by trypsinization and combined with cells floating in the medium. The apoptotic cells were
then determined with flow cytometry. (*) p #0.05 compared with mock. B) Apoptosis in cycE-overexpressing cells are confirmed by TUNEL assay. Two
days after siRNA transfection, the indicated cells were subjected to TUNEL analysis. Upper panel: apoptotic cells (purple staining) were detected in
MDA-MB436, but not in T47D cells. Lower panel: Percentage of apoptotic cells in the above two breast cancer cells treated with cycE or control siRNA.
C) S phase population is decreased by cycE siRNA in cycE-overexpressing cells. Treated cells were collected 48 h after transfection of cycE siRNA in
three cycE-overexpressing cells (SK-BR3, MDA-MB436 and MDA-MB157) and two cycE-low expressors (T47D and MDA-MB453). The cell cycle pattern
(G0/G1, S and G2/M) was also determined by flow cytometry. Three individual experiments were performed. (*) p#0.05 compared with mock in G0/
G1 population, (**) p#0.05 compared with mock in S population.
doi:10.1371/journal.pone.0012860.g002
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oligo targeting firefly luciferase mRNA (Luc) had no effect on cycE
expression levels (Figure 1A). Moreover, siRNA oligos did not
cause nonspecific downregulation of gene expression, as demon-
strated by b-actin control (Figure 1A). These data indicate that
cycE siRNA can effectively suppress the overexpression of both full
length and LMW isoforms of cycE.
Apoptosis and G1 arrest are induced in breast cancer
cells by siRNA-mediated depletion of cycE
overexpression
Since cycE and its functional complex cycE-Cdk2 play pivotal
roles in G1/S transition, we next examined pattern changes of the
cell cycle distribution and apoptosis in cycE-depleted cells. To
determine if depletion of cycE promotes tumor cell death, flow
cytometry was performed after transfection of the siRNAs. The
cells were analyzed at different time points (72 h and 96 h) post-
transfection and significant sub-G1 (apoptotic) populations were
observed at 96 h in cycE-overexpressing cells (SK-BR3, MDA-
MB157 and MDA-MB436); about 14% of these cells underwent
apoptosis after transfection of cycE siRNA (Figure 2A, left panel).
In contrast, only ,4% of the same cell lines underwent apoptosis
in the mock or luciferase siRNA-treated groups (Figure 2A, right
panel). The cycE-overexpressing cells shrank, rounded up and
detached from plates three days after transfection of cycE siRNA
while the control siRNA treated group remained attached on the
dishes and showed normal morphology, also suggesting that
apoptosis had occurred. In addition, we confirmed the cycE
siRNA-induced apoptosis in cycE-overexpressing cells by TUNEL
assay (Figure 2B, a & b). Notably, in contrast to the cycE-
overexpressing cells, we did not observe significant apoptosis in
cycE-low expressing cells (MDA-MB453 and T47D) at 96 h after
transfection (Figure 2A, right panel and Figure 2B, c & d),
although the cycE protein level in these cells was effectively
suppressed by cycE siRNA (Figure 1). These data reveal that
depletion of cycE specifically triggers apoptosis in the cycE-
overexpressing cells.
Additionally, 48 h after cycE siRNA transfection, we observed
increased G0/G1 and decreased S phase population in all three
cycE-overexpressing cell lines tested but not in cycE-low
Figure 3. Inhibition of cell transformation by cycE siRNA in vitro. A) Growth curves of breast cancer and normal epithelial cells in response to
cycE siRNA. The viable cells were counted at the indicated time points after transfection of siRNA oligos. The data shown here represent the averages
from three independent experiments. B) Suppression of colony formation in soft agar by cycE siRNA. The indicated cells were transfected with siRNA
targeting on cyclin E (cycE) or luciferase (Luc) and then seeded in 0.35% agar containing DMEM with 10% FBS. The cells without any oligo transfection
(mock) were used as a control. The cell viability for each group (mock, Luc, or cycE) was determined by colony formation assay. The number of
colonies on soft agar was counted 3-5 weeks later and was normalized by their cell viability. The normalized number of colonies on soft agar for the
groups of Luc or cycE was standardized against the control cells (mock, set at 100%) and indicated on the y axis. The data were the averages from two
independent triplicate experiments. (*) p#0.001 compared with mock.
doi:10.1371/journal.pone.0012860.g003
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results together indicate that cycE siRNA exhibits a specific
inhibitory effect on cycE-overexpressing breast cancer through
promotion of apoptosis as well as inhibition of G1/S phase
transition.
Depletion of cycE inhibits proliferation and
transformation in the cycE-overexpressing breast cancer
cells
To determine whether cycE siRNA actually affects proliferation
of breast cancer cells, we examined the growth curves of three
cycE-overexpressing cell lines and two cycE-low expressors in
response to cycE siRNA treatment. As shown in Figure 3A, cycE
siRNA significantly decreased the cell number of all three cycE-
overexpressing cell lines (SK-BR3, MDA-MB157 and MDA-
MB436) as compared to the control. However, for the cycE-low
expressing cells (T47D and MDA-MB453) or normal breast
epithelial cells (MCF10A), the cell number was not attenuated
dramatically after cycE siRNA transfection (Figure 3A). CycE
depletion also inhibited the transformation phenotype of cycE-
overexpressing cells. As shown in the Figure 3B and Figure S1,
cycE siRNA significantly reduced the ability of SK-BR3 to grow
on soft agar, a well known assay that measures cell transformation.
The transformation-suppressing activity was also observed in
MDA-MB157 and MDA-MB436 cell lines when we depleted their
cycE’s expression (data not shown). In contrast, we did not observe
significant transformation inhibitory effects on T47D (Figure 3B
and Figure S1) and MDA-MB453 (data not shown) by cycE
siRNA targeting. Taken together, cycE siRNA can dramatically
inhibit proliferation and transformation of the cycE-overexpress-
ing breast cancer cells.
CycE siRNA treatment is able to suppress tumor growth
in vivo
To determine whether cycE siRNA could suppress breast cancer
growth in vivo, we established breast tumors in nude mice and then
treated them with cycE siRNA. MDA-MB436 cells can easily grow
tumors in nude mice and, thus, we mainly selected this cycE-
overexpressing cell line to establish the tumor model in the
mammary glands of the nude mice. MDA-MB436 cells were
injected into the mouse mammary glands (two injected points per
mouse). About two weeks later, the nude mice with tumor burden
(n=15 for each group) were treated with indicated siRNA complex
or liposome alone (mock) by intratumoral injection. CycE or control
siRNA treatment was administered weekly for 4 weeks. As shown in
Figure 4A, we found that tumor growth in the cycE siRNA group
was dramatically inhibited as compared to the controls. To further
assess if cycE siRNA was able to suppress the tumor growth, we did
not treat the mice with the siRNA until the tumor burden in each
site reached over ,50 mm
3 at around 4 weeks after tumor cell
injection. After 4 weeks treatment, the tumor progression from the
cycE siRNA treatment group was significantly suppressed
(Figure 4B), which demonstrated cycE siRNA’s inhibitory ability
on the established tumors. In addition, Western blots and
immunohistochemistry analysis showed that cycE protein levels
were also decreased in most of the cycE siRNA-treated tumors
(Figure 4, C & D). Indeed, we observed much fewer cells with cycE
overexpression in tumors treated with cycE siRNA as compared to
those treated with PBS or control siRNA (Luc siRNA) (Figure 4D,
cycE siRNA panel). Furthermore, TUNEL assay showed that more
apoptotic cells were in the cycE siRNA-treated tumors (Figure 4E),
indicating that cycE depletion was able to induce apoptosis in vivo
and as a result, led to tumor suppression. We also tested the
inhibitory efficacy of cycE siRNA on another cycE-overexpressing
line, SK-BR3 as well as T47D, a cycE-low expressing line by
tumorigenecity assay. We found that treatment of cycE siRNA
could dramatically inhibit the tumor growth of SK-BR3 while this
treatment exerted only mild suppressing effect on T47D growth in
mice (Figure 4F). Taken together, treatment of cycE siRNA can
inhibit cycE-overexpressing breast tumor growth in vivo, indicating
that cycE siRNA may serve as a novel therapeutic agent for treating
breast cancer with cycE overexpression.
Synergistic inhibitory effects are achieved by
combination of cycE siRNA and Dox
To broaden the potential clinical applications, we tested if there
was any synergistic effect on breast cancer cell growth by
combination of cycE siRNA with Dox (50 ng/ml), a chemother-
apeutic drug commonly used to treat breast cancer patients
[28,29]. SK-BR3 and MDA-MB436 cells were treated with cycE
siRNA or Dox alone, or in combination. We found that
Figure 4. Tumor growth in vivo is dramatically inhibited by cycE siRNA. A) The growth of MDA-MB436 tumor xenografts is suppressed by
cycE siRNA treatment. The MDA-MB436 cells were injected into the mammary glands of the nude mice. At around 2 weeks after tumor cell injection,
the mice with tumor burden were randomly grouped (n=15 for each group) and treated weekly by intumoral injection over 4 weeks with indicated
siRNA (10 mg) or liposome alone (mock). Arrows indicated the days when mice were administered. Tumor size was measured weekly before each
administration. The treated mice were sacrificed at day 40 post tumor cell injection and tumor samples were collected. Representative tumor samples
from each indicated treatment group were shown in the right panel and the tumors from cycE-siRNA treated groups were much smaller as compared
to mock or Luc-siRNA groups. (*) p#0.05 compared with mock. Scale unit: 1 cm. B) Growth inhibition of the established tumor xenografts (,50 mm
3)
by cycE siRNA. The MDA-MB436 cells were injected into the mammary glands of the nude mice. When the tumor size reached to , 50 mm
3 at
around 4 weeks after tumor cell injection, the mice were randomly grouped (n=15 for each group) and treated weekly by intratumoral injection for 4
weeks without (mock) or with indicated siRNA (10 mg). Arrows indicated the days when mice were administered. The treated mice were sacrificed at
day 56 post tumor cell injection and tumor samples were collected. Representative tumor samples from each indicated treatment group were shown
in the right panel. (*) p#0.05 compared with mock. Scale unit: 1 cm. C) Assessment of reduced cycE protein levels in cycE siRNA-treated tumors.
MDA-MB436 tumors from indicated treatment groups were collected 2 days after the last treatment with mock (M) or indicated siRNA and analyzed
for cycE protein levels by Western blots using anti-cycE or anti-actin antibodies. Here shown are the representative results from the indicated samples
of each group in A. M: Mock. D) Confirmation of reduced CycE expression in response to cycE siRNA treatment by immunostaining. MDA-MB436
tumors from indicated treatment groups were sectioned and analyzed for cycE expression using anti-cycE immunohistochemical staining (left
panels). For each tumor sample, 1000 cells were counted, and the cycE-positive cells were summarized in the right panel. (*) p#0.01 compared with
mock (M). Scale bar, 25 mm. E) Apoptosis is induced in the cycE siRNA-treated tumors. Apoptosis was examined by TUNEL assay in MDA-MB436 tumor
sections with indicated treatment. For each tumor sample, 1000 cells were counted, and the apoptotic cells were summarized in the right panel.
(*) p#0.01 compared with mock (M). Black arrows, apoptotic cells. Scale bar, 25 mm. F) CycE siRNA treatment dramatically inhibits tumor growth of
SK-BR3 but not the growth of T47D in mice. SK-BR3 cells or T47D cells were injected into the mammary glands of the nude mice, respectively. On day
14 after implantation of tumor cells, the mice were treated weekly for 4 weeks with indicated siRNA (10 mg) or liposome alone (mock) (n=15 for each
group). Arrows indicated the days when mice were administered. Tumor size was measured weekly before each administration. (*) p#0.05 compared
with mock.
doi:10.1371/journal.pone.0012860.g004
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cell-killing effect than cycE siRNA alone or Dox alone in both cell
lines (Figure 5A), while Dox at 50 ng/ml had no apparent effects
on expression level of cycE in SK-BR3 and MDA-MB436
(Figure 5B). To determine if this inhibitory effect was synergistic,
we calculated the combination indexes (CI) using the CI-
isobologram method developed by Chou-Talalay [26,27]. As
shown in Figure 5C, CIs at IC90 and IC95 were both less than 1
for SK-BR3 and MDA-MB436 cells, indicating there was
synergistically inhibitory effect on these cancer cells by combina-
tion of the cycE siRNA with Dox. In addition, we examined the
therapeutic effect of this combinational treatment in mice. About
14 days after inoculation of MDA-MB436 cells, the animals were
divided into 5 groups (n=15 for each group). For the groups of
mock, Luc siRNA and cycE siRNA, the mice were treated with
liposome alone (mock), Luc siRNA, and cycE siRNA, respectively,
by weekly repeated intratumoral injection for 4 weeks. For the
Dox alone group, the mice were treated with Dox by weekly
intraperitoneal injection for 4 weeks, and for the Dox + cycE
siRNA group, the mice were administered with Dox by weekly
intraperitoneal injection following cycE siRNA treatment on the
next day for 4 weeks. We found that administration of cycE siRNA
combined with Dox was able to suppress tumor growth of MDA-
MB436 with a much stronger effect than cycE siRNA oligos alone
or Dox alone (Figure 5D). Together, combination of cycE siRNA
with Dox may provide a novel treatment option for breast cancer
with cycE overexpression.
Discussion
CycE is aberrantly expressed in many types of cancer [14,30–32].
Indeed, high levels of the wild-type and LMW isoforms of cycE are
associated with poor prognosis of breast cancer patients [14].
Importantly, cycE overexpression is also correlated with triple-
negative (ER-, PR-, and HER2-negative) basal-like breast cancers
[33] which lack specific therapeutic targets. In this study, we used
cycE siRNA to target cycE overexpression and assessed its ability to
suppress breast cancer growth in nude mice. Our results revealed
that cycE siRNA effectively inhibited the cycE overexpression of
both full length and LMW isoforms (Figure 1). Depletion of cycE
promoted apoptosis of cycE-overexpressing cells and blocked their
proliferation and transformation phenotype (Figures 2 and 3). We
also showed that cycE siRNA inhibited breast tumor growth in nude
mice (Figure 4). In addition, we found that cycE siRNA
synergistically enhanced the cell killing effects of Dox in cell culture
and this combination greatly suppressed tumor growth in mice
(Figure 5). Thus, our study clearly demonstrates the therapeutic
potential of cycE siRNA for treating cycE-overexpressing breast
cancer, including triple-negative breast cancer. Our results also
indicate that cycE, which is overexpressed in 30% of breast cancer,
may serve as a novel and effective therapeutic target.
Although the full length cycE is usually expressed in both
normal and tumor cells, the LMW cycE isoforms are predomi-
nantly expressed in tumor cells. These LMW isoforms of cycE are
mainly post-translationally processed by proteinase (e.g. elastase)
in tumor cells to produce two sets of doublets with subsequent
modifications when observed in Western blots (33–35 kDa, and
44–45 kDa) [13,34]. LMW cycE isoforms function in the same
manner as the full length proteins, and show increased binding
efficiency to its partner kinase CDK2, leading to accelerated entry
to S phase and genomic instability [35,36]. Importantly, as we
demonstrated above, our cycE siRNA effectively inhibited not
only expression of the full length but also LMW isoforms of cycE
proteins, which, in turn, led to suppression of cell growth and
Figure 5. Enhanced inhibitory effects by combination of cyc E
siRNA with Dox. A) Sensitization of breast cancer cells to Dox by
treatment of cyc E siRNA. Indicated breast cancer cells (1610
5/well in 6-
well plates) were transfected with cyc E siRNA (0.1 mg/well) for 24 hours.
The cells were then split into 96-well plates (2610
3 cells/well) and treated
withDox(50 ng/ml)for8days.MTTassaywasperformedtodeterminecell
viability. Y-axis represented the relative MTT value from each treatment.
(*) p#0.05 compared with mock. B) CycE levels are not affected by Dox.
CycE-overexpressing breast cancer cells (SK-BR3 and MDA-MB436) were
treated without or with siRNA alone, Dox (50 ng/ml) alone or in
combination for 48 h. Treated cells were collected and the lysates were
subjectedtoWesternblotanalysiswithanti-cycEandanti-Actinantibodies,
respectively.C) Synergistic cytotoxicityby combination ofcyc E siRNAwith
Dox. SK-BR3 and MDA-MB436 cells were treated with different concen-
tration of siRNA (0–0.1 mg/well in six-well plates) and split into 96-well
plates. After 8 days incubation with different concentration of Dox (0–
100 ng/ml), cytotoxicity was determined by MTT assay. The CIs were
calculated using the CI-isobologram method by Chou-Talalay. CI=1
indicates an additive effect; CI,1 indicates synergism; CI.1i n d i c a t e s
antagonism. Data plotted are the CI value at 80, 90 and 95% fraction killed
and are means of three independent experiments; bars, SD. D)C y c Es i R N A
in combination with Dox is able to effectively inhibit the breast tumor
growth in mice. MDA-MB436 cells were injected into the mammary glands
of the nude mice. Beginning on day 14 post tumor cell injection, the mice
were weekly treated with cycE siRNA (10 mg/injection), luciferase siRNA
(Luc-siRNA), liposome alone (mock), Dox alone (2 mg/kg body weight via
intraperitoneal injection) or cycE siRNA + Dox over 4 weeks as described in
Methodssection.Arrowsindicatedthedayswhenmicewereadministered.
The effects of treatment on tumor growth were determined by weekly
measuring tumor volume. Dox: doxorubicin. (*) p#0.05 and (**) p#0.01
compared with mock (M) after 4 administrations.
doi:10.1371/journal.pone.0012860.g005
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treatment can reverse the malignancy of breast cancer induced
by overexpression of both wild-type and LMW isoforms of cycE.
High level of cycE correlates with triple-negative breast cancers
[33]. Indeed, two of three cycE-overexpressing cell lines that were
used in this study (MDA-MB436 and MDA-MB157) are triple-
negative cancer cells [24]. Notably, cycE siRNA alone (Figures 3
and 4) or in combination with Dox (Figure 5) can effectively inhibit
the growth of these cancer cells both in vitro and in mice. Thus, this
combination therapy may serve as an effective treatment option
for triple-negative breast cancers since there are no specific
treatment guidelines for the triple-negative cancers, which appear
to be very metastatic and have a poor prognostic outcome.
Our results demonstrate that cycE siRNA exerts robust anti-
tumor activity via promoting apoptosis and inhibition of DNA
replication. The induced apoptosis is only observed in cycE-
overexpressing cells (SK-BR3, MDA-MB157 and MDA-MB436)
but not in cycE-low expressing cells (MDA-MB453 and T47D),
and this specificity should increase the therapeutic index of
siRNA-based therapies for cycE-overexpressing cancers. It is
unclear how cycE depletion triggers apoptosis in cycE-overex-
pressing cells. However, it is well known that tumor cells are highly
dependent on an activated oncogene for their survival and/or
proliferation, a phenomenon called ‘‘oncogene addiction’’ [37].
Inactivation of these activated oncogenes leads to apoptosis and
anti-tumor functions. The most convincing evidence for the
concept of oncogene addiction comes from the examples of
therapeutic efficacy of antibodies or drugs that target specific
oncogenes in human cancers such as the antibody trastuzumab
(Herceptin), which targets the receptor tyrosine kinase HER-2/
NEU in breast cancer. Our studies here support that cycE-
overexpressing cancers are cycE addiction, i.e., highly rely on the
activity of cycE for continued cell proliferation and survival.
Importantly, in addition to promotion of apoptosis, depletion of
cycE by its siRNA sensitizes the cell killing effect of Dox in the
cycE-overexpressing breast cancer cells. Dox is a chemodrug
targeting S-phase cells via inhibition of the topoisomerase II
(TOP2) [38]. Our flow cytometry data show that depletion of cyc
E does not lead to accumulation of cells in S phase, suggesting that
sensitization to Dox is directed through mechanisms other than S-
phase accumulation. Interestingly, it has been shown that the cell
survival pathways such as NF-e ˆB, Akt and Bcl-2 family can be
activated to antagonize the cytotoxic effects of Dox [39-41]. Also,
blockage of these pathways sensitizes breast cancer cells to Dox
[39]. Therefore, in the future, it will be interesting to investigate if
cycE overexpression may enhance the survival pathways and
therefore increase the resistance to Dox.
A potential concern for siRNA therapy is the delivery
effectiveness of siRNA in vivo. In this study, cycE siRNA was
delivered using liposome by intratumoral injection and we
demonstrated this regime being sufficient to inhibit cycE
expression in vivo and as a result, led to tumor suppression. CycE
siRNA used here for treatment is a non-chemically-modified
siRNA, which has relatively limited in vivo stability and membrane
permeability. To apply cycE siRNA therapy in clinic in the future,
it will be greatly beneficial if we can modify this siRNA to reduce
its sensitivity to nucleases and increase its cellular uptake.
Recently, various approaches have been adapted to chemically
modify the siRNAs to increase its nuclease resistance as well as its
intracellular uptake [17,42,43]. Thus, it will be of great interest to
test if chemical modifications of our cycE siRNA will improve its
therapeutic efficacy, especially for systematic treatment in mice. In
addition to chemical modification of siRNA, novel delivery
systems can be employed to improve stability and efficacy of cycE
siRNA [17], such as carrying siRNA by targeted nanoparticles to
further improve the therapeutic efficacy of cycE siRNA in the
future.
Supporting Information
Figure S1 Cyclin E siRNA inhibits colony formation in soft agar
in cyclin E-overexpressing cells, but not in cyclin E-low expressing
cells. Here shown are the representative data of colony formation
in soft agar from SK-BR3 (top panel) and T47D (bottom panel).
The viability of each group (%) was monitored as described in
Methods section, and indicated at the bottom of each panel.
Found at: doi:10.1371/journal.pone.0012860.s001 (9.73 MB TIF)
Author Contributions
Conceived and designed the experiments: SYL KL. Performed the
experiments: YL HG KL. Analyzed the data: YL SYL KL. Contributed
reagents/materials/analysis tools: JAG FCB. Wrote the paper: YL KL.
References
1. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, et al. (1992) Formation
and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell
cycle. Science 257: 1689–1694.
2. Sauer K, Lehner CF (1995) The role of cyclin E in the regulation of entry into S
phase. Prog Cell Cycle Res 1: 125–139.
3. Malumbres M, Barbacid M (2001) To cycle or not cycle: a critical decision in
cancer. Nature Rev Cancer 1: 222–231.
4. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM (1996) Turnover of
cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and
cyclin phosphorylation. Genes Dev 10: 1979–1990.
5. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK (2001)
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human
cancer cell lines. Nature 413: 311–316.
6. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, et al. (2001) Human
F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast
cancer cell line. Nature 413: 316–322.
7. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, et al. (2001)
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7
ubiquitin ligase. Science 294: 173–177.
8. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces
chromosome instability. Nature 401: 297–300.
9. Wingate H, Puskas A, Duong M, Bui T, Richardson D, et al. (2009) Low
molecular weight cyclin E is specific in breast cancer and is associated with
mechanisms of tumor progression. Cell Cycle 8: 1062–1068.
10. Bortner DM, Rosenberg MP (1997) Induction of mammary gland hyperplasia
and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol
17: 453–459.
11. Nielsen NH, Arnerlo ¨v C, Emdin SO, Landberg G (1996) Cyclin E
overexpression, a negative prognostic factor in breast cancer with strong
correlation to oestrogen receptor status. Br J Cancer 74: 874–880.
12. Keyomarsi K, O’Leary N, Molnar G, Lees E, Fingert HJ, et al. (1994) Cyclin E,
a potential prognostic marker for breast cancer. Cancer Res 54: 380–385.
13. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, et al. (2001)
Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-
molecular-weight forms. Mol Cell Biol 21: 6254–6269.
14. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, et al. (2002)
Cyclin E and survival in patients with breast cancer. N Engl J Med 347:
1566–1575.
15. Sharp PA (2001) RNA interference-2001. Genes Dev 15: 485–490.
16. Hannon GJ (2002) RNA interference. Nature 418: 244–251.
17. Kim DH, JJ Rossi (2007) Strategies for silencing human disease using RNA
interference. Nat Rev Genet 8: 173–184.
18. Braasch DA, Corey DR (2002) Novel Antisense and Peptide Nucleic Acid
strategies for controlling gene expression. Biochemistry 41: 4503–4510.
19. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, et al. (2002)
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.
Biochem Biophys Res Commun 296: 1000–1004.
20. Hough SR, Wiederholt KA, Burrier AC, Woolf TM, Taylor MF (2003) Why
RNAi makes sense. Nat Biotechnol 21: 731–732.
21. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of
tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243–247.
22. Wilda M, Fuchs U, Wo ¨ssmann W, Borkhardt A (2002) Killing of leukemic cells
with a BCR/ABL fusion gene by RBA interference (RNAi). Oncogene 21:
5716–5724.
Cyclin E siRNA-Based Therapy
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e1286023. Li K, Lin SY, Brunicardi FC, Seu P (2003) Use of RNA interference to target
cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 63: 3593–3597.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10: 515–527.
25. Li K, Shao R, Hung MC (1999) Collagen-homology domain 1 deletion mutant
of Shc suppresses transformation mediated by neu through a MAPK-
independent pathway. Oncogene 18: 2617–2626.
26. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 22:
27–55.
27. Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, et al. (2002)
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel
in human breast cancer cell lines in vitro and in vivo. Cancer Res 62:
6909–6915.
28. Overmoyer BA (1995) Chemotherapeutic palliative approaches in the treatment
of breast cancer. Semin Oncol 22: 2–9.
29. Jin W, Wu L, Liang K, Liu B, Lu Y, et al. (2003) Roles of the PI-3K and MEK
pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer
89: 185–191.
30. Jang SJ, Park YW, Park MH, Lee JD, Lee YY, et al. (1999) Expression of cell-
cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for
gastric cancer. Eur J Sur Oncol 25: 157–163.
31. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K (2004) Cyclin E
deregulation alters the biologic properties of ovarian cancer cells. Oncogene
23: 2648–2657.
32. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, et al.
(2005) The low molecular weight cyclin E isoforms augment angiogenesis and
metastasis of human melanoma cells in vivo. Cancer Res 65: 692–697.
33. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, et al. (2004)
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/
glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast
cancer. Cancer Res 64: 830–835.
34. Harwell RM, Porter DC, Danes C, Keyomarsi K (2000) Processing of cyclin E
differs between normal and tumor breast cells. Cancer Res 60: 481–489.
35. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, et al. (2005) The
tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21
and p27. J Biol Chem 280: 15148–15157.
36. Wingate H, Puskas A, Duong M, Bui T, Richardson D, et al. (2009) Low
molecular weight cyclin E is specific in breast cancer and is associated with
mechanisms of tumor progression. Cell Cycle 8: 1062–1068.
37. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077–3080.
38. van Hille B, Perrin D, Hill BT (1999) Differential in vitro interactions of a series
of clinically useful topoisomerase-interacting compounds with the cleavage/
religation activity of the human topoisomerase IIalpha and IIbeta isoforms.
Anticancer Drugs 10: 551–560.
39. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, et al. (2002) Role of Rel/NF-
kappaB transcription factors in apoptosis of human hepatocellular carcinoma
cells. Cancer 95: 1696–1705.
40. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, et al. (2003) HER2/PI-3K/Akt
activation leads to a multidrug resistance in human breast adenocarcinoma cells.
Oncogene 22: 3205–3212.
41. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, et al. (2003)
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer
response to chemotherapy. Cancer J 9: 33–41.
42. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, et al. (2004)
Therapeutic silencing of an endogenous gene by systemic administration of
modified siRNAs. Nature 432: 173–178.
43. Goyal BR, Patel MM, Soni MK, Bhadada SV (2009) Therapeutic opportunities
of small interfering RNA. Fundam Clin Pharmacol 23: 367–386.
Cyclin E siRNA-Based Therapy
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12860